Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Gains from Investment Securities (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Gains from Investment Securities for 8 consecutive years, with $3632.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 100.93% year-over-year to $3632.0, compared with a TTM value of -$391593.0 through Dec 2025, up 8.98%, and an annual FY2025 reading of $6.1 million, up 396.31% over the prior year.
  • Gains from Investment Securities was $3632.0 for Q4 2025 at Neuroone Medical Technologies, up from -$906516.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.7 million in Q3 2023 and bottomed at -$906516.0 in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $200284.8, with a median of -$14254.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 6296.01% in 2023, then crashed 2972.23% in 2024.
  • Year by year, Gains from Investment Securities stood at -$26235.0 in 2021, then dropped by 2.05% to -$26772.0 in 2022, then soared by 150.65% to $13559.0 in 2023, then plummeted by 2972.23% to -$389445.0 in 2024, then skyrocketed by 100.93% to $3632.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for NMTC at $3632.0 in Q4 2025, -$906516.0 in Q3 2025, and $901642.0 in Q2 2025.